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How Much do Needlestick Injuries Cost? A Systematic Review of the
Economic Evaluations of Needlestick and Sharps Injuries Among
Healthcare Personnel
Alice Mannocci, PhD, MS;1 Gabriella De Carli, MD;2 Virginia Di Bari, PhD, MD;2 Rosella Saulle, MD;1 Brigid Unim, MD;1
Nicola Nicolotti, MD;2 Lorenzo Carbonari, PhD;3 Vincenzo Puro, MD;2 Giuseppe La Torre, DSc1
objective. To provide an overview of the economic aspects of needlestick and sharps injury (NSI) management among healthcare personnel
(HCP) within a Health Technology Assessment project to evaluate the impact of safety-engineered devices on health care
methods. A systematic review of economic analyses related toNSIs was performed in accordance with the PRISMA statement and by searching
PubMed and Scopus databases (January 1997–February 2015). Mean costs were stratified by study approach (modeling or data driven) and type of
cost (direct or indirect). Costs were evaluated using the CDC operative definition and converted to 2015 International US dollars (Int$).
results. A total of 14 studies were retrieved: 8 data-driven studies and 6 modeling studies. Among them, 11 studies provided direct and indirect
costs and 3 studies provided only direct costs. Themedian of themeans for aggregate (direct + indirect) costs was Int$747 (range, Int$199–Int$1,691).
The medians of the means for disaggregated costs were Int$425 (range, Int$48–Int$1,516) for direct costs (9 studies) and Int$322 (range, Int$152–Int
$413) for indirect costs (6 studies). When compared with data-driven studies, modeling studies had higher disaggregated and aggregated costs, but
data-driven studies showed greater variability. Indirect costs were consistent between studies, mostly referring to lost productivity, while direct costs
varied widely within and between studies according to source infectivity, HCP susceptibility, and post-exposure diagnostic and prophylactic protocols.
Costs of treating infections were not included, and intangible costs could equal those associated with NSI medical evaluations.
conclusions. NSIs generate significant direct, indirect, potential, and intangible costs, possibly increasing over time. Economic efforts
directed at preventing occupational exposures and infections, including provision of safety-engineered devices, may be offset by the savings from
a lower incidence of NSIs.
Infect. Control Hosp. Epidemiol. 2016;1–12
Occupational exposures of healthcare personnel (HCP), espe-
cially nurses and surgeons, to bloodborne pathogens are frequent
events in hospitals.1 In Italy every day, ~300 HCP sustain an
injury involving a contaminated needle or sharp medical device
(needlestick and sharps injuries, NSIs), totaling >100,000 acci-
dents per year, but only an estimated 45% are officially reported.2
Similar figures are available for the United States where, before
legislation mandated widespread implementation of needlestick-
prevention devices incorporating a safetymechanism to cover the
tip after use (safety-engineered devices, SEDs), 385,000NSIs were
estimated to occur annually, 60% of which were unreported.3
Available data from other European countries and all continents
clearly demonstrate the high NSI burden worldwide.4–8
These NSIs have the potential to transmit virtually every
pathogen present in human blood, either transiently or
persistently.9,10 However, hepatitis B virus (HBV), hepatitis C
virus (HCV), and human immunodeficiency virus (HIV), all
bearing significant morbidity and mortality, together account
for the vast majority of occupational infections reported in
healthcare. In 2000, in the absence of interventions to prevent
NSIs, these agents were estimated to have caused >80,000 new
infections among HCP per year worldwide.11
Therefore, administrative, behavioral, and technical inter-
ventions aiming to reduce NSI frequency have been progres-
sively introduced, including recommendations to prevent
improper needle manipulations,12 education,13 provision of
sharps containers for appropriate elimination of used devi-
ces,14 and SEDs.15,16 Each intervention has contributed to
decreasing NSI frequency, but the best preventative strategy
(ie, incorporating all these elements), requires significant
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investments of time, resources, and effort, which has limited
their widespread implementation.17
Preventive interventions have therefore been included and
have thus been reinforced in specific regulations regarding
safety at work. In the United States, the Needlestick Safety and
Prevention Act was passed in 2000,18 and the Occupational
Safety and Health Administration endorsed the use of safe
needles or needleless devices for the collection and/or
withdrawal of body fluids and for the administration of fluids
and medications.19,20 In Europe, the Council Directive 2010/
32/EU, “Prevention from sharp injuries in the hospital and
healthcare sector,” fully in force since 2013, protects HCP
from NSIs and their consequences, setting up integrated
policies regarding risk assessment, risk prevention, training,
education, and monitoring. Among the prevention measures,
SEDs must be made available based on risk assessment,
whereas HBV vaccination must be universally provided free of
charge. Monitoring includes investigating the causes and
circumstances of the accident and immediate care for the
injured HCP that includes post-exposure prophylaxis (PEP),
the necessary medical tests, health surveillance, and counseling
where appropriate. Additionally, medical treatment is
guaranteed. The economic impact of this directive is expected
to be significant.21
Several studies have considered the economic burden of
occupational NSIs,22–25 mostly providing direct costs (ie, post-
exposure management) and indirect costs (ie, counselling NSI
victims, staff absence and compensation) from different
perspectives and, more rarely, evaluating NSIs reduction after
the introduction of preventive measures and the resulting
economic impact. However, these studies vary widely in terms
of setting, source of epidemiologic data, and considered costs,
making it difficult to define a standardized cost for NSI
management and prevention.
Given the increased costs of SEDs compared to conven-
tional devices, in 2012, a Health Technology Assessment
project was launched in Italy to evaluate this new technology
and its overall impact on health care, including an economic
analysis of costs deriving from NSIs and savings arising from
their prevention. This systematic review represents the first
part of this project.
materials and methods
A systematic review of economic analyses of occupational NSIs
among HCP was performed in accordance with the PRISMA
statement.26 Independently, 2 authors consulted PubMed and
Scopus databases and resolved eventual discrepancies by
consulting a third author. The research algorithm used the
following keywords: “cost, needlestick injuries” and “cost,
occupational exposures, blood injuries.” Inclusion criteria
were language (English, Italian, French, or Spanish) and
publication date (January 1997–February 2015).
The titles and abstracts of all articles were evaluated,
eliminating duplicates. Articles were then assessed for
eligibility through a full-text examination, and an article was
included in the analysis if it provided an original estimate of
either direct or indirect costs of managing a single NSI. The
main stages of the systematic review are shown in Figure 1.
Categorization and organization of the reference list were
performed using JabRef 2.7.2 software.
Data extraction forms included author’s name, publication
year, country, source of the occurrence data, study period,
population studied, NSI incidence, perspective, cost estimating
approach (modeling or data-driven), items considered in cost,
type of cost studied (direct and/or indirect), injury manage-
ment cost (range), and currency equivalent.
To compare monetary values expressed in different
currencies and for different years, the national inflation rates
provided by the World Bank (http://data.worldbank.org/indi-
cator/fp.cpi.totl.zg) were used to express the injury manage-
ment costs in national currencies 2015. These values were then
converted to 2015 International US dollars (Int$) using
purchasing power parity (ppp) exchange rates (http://data.
worldbank.org/indicator/pa.nus.ppp). To facilitate compar-
isons, all costs included in this review were converted to Int$.
Data were analyzed by computing mean, median, and
standard deviation (SD) as well as minimum and maximum
figure 1. Flow-chart of the selection process. *Language other
than English, Italian, French or Spanish, or published before
January 1997. **Study references were examined to identify other
eligible studies.
2 infection control & hospital epidemiology
mean costs abstracted from each article. The weighted mean
was used to account for the different proportion of resources
used according to the type of event. The findings were strati-
fied by study approach and type of cost (direct and/or indir-
ect). All data used in this analysis were true cost data.
Direct and indirect costs of an NSI were evaluated using the
CDC operative definitions:
1. Direct costs: Costs generally borne by a healthcare orga-
nization when an NSI occurs: baseline and follow-up
laboratory testing, PEP, and other treatment eventually pro-
vided, including PEP side-effect management. According to
which costs are borne by the organization, in certain circum-
stances, workers’ compensation or the management of occu-
pationally exposed HCP may be included with direct costs.
2. Indirect costs: These costs include time and wages
diverted to receiving or providing exposure-related care: lost
productivity associated with reporting and receiving initial and
follow-up treatment for the exposure; healthcare provider
time to evaluate and treat an employee; and healthcare
provider time to evaluate and test the source, including
obtaining informed consent for testing if applicable. For
occupational health and infection control practitioners, these
measures are part of their job responsibilities and therefore are
not considered a diversion. Moreover, when staff absence and
compensation are borne by a third-party payer, these may not
be included with indirect costs.27
When analyzing in detail the items included within direct
and indirect costs in each study, the authors originally assigned
baseline and follow-up post-exposure visits differently
according to the study context. However, when stratifying the
study findings, the post-exposure visits, when disaggregated,
were always considered as a direct cost and were assigned
accordingly.
The quality of each study was evaluated using Drummond’s
checklist modified by La Torre et al.28
results
In total, 14 studies from Europe, America, Asia, and Australia
published from 1997 to 2013 met all the inclusion
criteria.8,17,22,24,25,29–37 Their characteristics are reported in
Tables 1 and 2.
Cost Analysis
Of the 14 studies estimating costs, 8 studies were data driven,
while 6 studies used modeling (Table 3); 11 studies provided
both direct and indirect costs (aggregated or disaggregated),
while 3 studies only analyzed direct costs (Tables 2 and 3).
Costs were analyzed mainly from a hospital or university
perspective in 7 studies8,17,24,25,29,32,36; 3 studies adopted the
National Health System (NHS) perspective22,31,33; and
1 study adopted both.30 A societal perspective was considered
in 2 studies,34,35 and a national insurance perspective was
considered in 1 study.37
Direct costs included testing the source and exposed HCP as
well as post-exposure medical visits and treatment (ie, pro-
phylaxis). Costs to treat an occupational infection were
included in 2 studies only, which reported annual treatment
costs32 and lifetime medical costs35 for HBV (Int$3,600 and
Int$31,306, respectively), HCV (Int$24,424 and Int$23,173,
respectively), and HIV infection (Int$35,745 and Int$441,342,
respectively). These were excluded from the calculation of
average NSI costs.
Indirect costs included lost productivity (time off work)
associated with the time required for reporting and receiving
initial and follow-up treatment as well as exposure con-
sequences (eg, absence due to emotional distress and anxiety),
overhead, compensation, and litigation.
Considering the 11 studies that provided aggregate direct +
indirect costs, the overall median of the means of costs for
managing an NSI was Int$747 (mean of means, Int$861; range
of means, Int$199– Int$1691) (Tables 2 and 4).
The median of the means of the 9 studies that estimated
disaggregated direct costs was Int$425 (mean, Int$554; range,
Int$48–Int$1,516), and the median of the means of the
6 studies that estimated disaggregated indirect costs was Int
$322 (mean, Int$286; range, Int$152–Int$413).
Considering the type of approach, modeling studies had
higher disaggregated and aggregated costs than data-driven
studies: direct cost ratio, 3.4:1; indirect cost ratio, 1.84:1;
combined direct + indirect cost ratio, 1.13:1. Costs from data-
driven studies, however, showed greater variability, with
standard deviations more than twice those of modeling studies
(Table 4).
When estimating direct and indirect NSI management costs,
the included cost items differed among studies (Table 5).
Regarding direct costs, while laboratory tests represented the
greater proportion in all studies, tests performed on the source
and exposed HCP varied greatly. In total, 12 studies provided
an itemized serological test menu.8,17,22,24,25,29–31,33,34,36,37 In
all studies, investigators screened the source for antibodies
against HCV (HCV-Ab) and HIV (HIV-Ab). HBV screening
was performed mainly using surface antigen
(HBsAg),8,24,25,29,30,31,34,36 adding surface antibody (HBsAb)22
or core antibody (HBcAb)33,37 or through HBcAb alone.17
Regarding HCP, in 4 studies,17,29,30,33 HCV-Ab and HIV-Ab
were always performed; in 6 studies,8,22,24,31,36,37 based on the
source serostatus; and in 2 studies,25,34 the tests were based on
HCP anxiety or other factor. HBV baseline screening varied;
HBsAb was performed in vaccinated HCP regardless of the
source,8 in case of a HBsAg-positive source,29 or following
exposure to a positive or unknown source.22,24,30,37 In 1 study,
unvaccinated HCP, or vaccinated HCP with unknown or
negative response, were tested for HBsAg, HBcAb, and HBsAb
when exposed to an HBsAg-positive or unknown source.36 In
another study, all HCP were tested only for HBcAb.17 Finally,
in 4 studies, HBV markers (usually HBsAg and Ab) were
performed regardless of the HCP vaccinal status or source
serostatus.25,31,33,34
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table 1. Characteristics of the Studies of Economic Analysis of Occupational Needlestick and Sharps Injuries (NSIs) Among Healthcare Personnel (HCP) Included in the
Systematic Review, 1997–2013
Country Source of Occurrence Data Study Period Population
Baseline NSI Incidence With
Conventional Devicesa
NSI Incidence After
Interventiona
Study
(Reference)
United States Longitudinal surveillance 2 y (June 1995–May 1997) HCP (hospital A: CH;
hospital B: UH)
Hospital A: 38.3/100 beds per
year; hospital B: 66/100 beds
per year
Not applicable 33
Spain Longitudinal surveillance 18mo (January 1993–August 1995) UH HCP 8.2/100 HCP per year Not applicable 37
France Longitudinal surveillance Baseline: 1 y (1990); after: 3 y (1995–
1997)
UH HCP 12.7/100,000 needles used 6.4/100,000 needles used
(education
seminars + SEDs)
17
France Longitudinal surveillance 1 y (2000) UH HCP 4.1/100 HCP per year Not applicable 36
United States Retrospective survey
(recall)
1 y (August 2003–August 2004) CH nurses 44.8/100 nurses per year Not applicable 34
Spain Longitudinal surveillance 5 y (January 1998–December 2002) UH HCP 7.7/100 HCP per year Not applicable 22
Italy Longitudinal surveillance
and systematic review
75% from national longitudinal
surveillance (2000–2003); 25%
from systematic review of literature
(2002–2005)
Hospital HCP Hospital A: 7.8/100,000 needles
used per year; hospital B:
18.4/100,000 needles used
per year.
Hospital A: 0.9/100,000
needles used per year;
hospital B:
2.2/100,000 needles used
per year (SEDs)
30
Spain Longitudinal surveillance 1 y (March 2002–Februay 2003) UH HCP 19.4/100 beds per year 7.2/100 beds per year (SEDs); 29
3.2/100 beds per year
(SEDs + education and/or
change in procedure)
United States Estimates from literature
data
1 y (1997–1998) Hospital and non-
hospital HCP
0.7/100 FTE in non-hospital
HCP; 1.6/100 FTE in hospital
HCP
Not applicable 35
United States Opportunistic sample
from longitudinal
surveillance
1 y (2003) HCP Not applicable Not applicable 24
Sweden Longitudinal surveillance 1 y (2002) HCP 3.14/100 FTE per year (1.89
with hollow-bore needles;
60% of the total)
1.1/100 FTE per year (SEDs) 31
Chile Longitudinal surveillance 5 y (2003–2007) University healthcare
students
0.9/100 students per year Not applicable 8
Belgium Estimates from literature
and market data
1 y (1999–2000) HCP Injection needles used
10.8/100,000;
Injection needles used 1.5/
100,000;
32
infusion therapy 26.0; infusion therapy 8.08;
insulin therapy 23.5; insulin therapy 3.3;
blood collection 23.4 blood collection 7.0 (SEDs)
Korea Longitudinal surveillance 4mo (October 2005–February 2006) CH HCP 2.9/100 FTE per year or
6.1/100 beds per year
Not considered 25
NOTE. CH, community hospital; FTE, full-time equivalent; HCP, healthcare personnel (doctors, nurses, technicians, students, etc.); NSIs, needlestick and sharps injuries; UH, university
hospital; SEDs, safety-engineered devices.
aNSI incidence rates were standardized according to the available denominator (100 beds; 100 FTE or HCP; 100,000 used devices).
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table 2. Economic Characteristics of the Studies of Economic Analysis on Occupational Needlestick and Sharps Injuries Among Healthcare Personnel Included in the Systematic Review,
1997–2013 (Temporal Publication Order)
Perspective Approach Determinants of Cost Type of Costa
Costs
According
to the CDC
Definitionb
Weighted Mean
Cost per Injury,
Int$ (Range) Currency/Year
Value per Injury,
Int$ (Range)c
Comments on
Economic Results
Study
(Reference)
NHS Data-driven Laboratory tests,
prophylaxis, lost
productivity (exposed
HCP and visiting staff)
Direct/indirect Yes Direct + indirect
Direct
Indirect
605 (197–1,094)
473 (NC)
250 (NC)
US$/1997 Direct + indirect
Direct
Indirect
893 (290–1,614)
698
369
Hospital A: $672
(range: $340-1025);
Hospital B: $539
(range: $197–1,094)
33
Third party
(Social
Security)
Modeling Laboratory tests,
prophylaxis, medical
visits, lost productivity
(exposed HCP, visiting
and administration
staff), overhead
Direct + indirect … Direct + indirect 39,564 (23,074–
86,864)
Pesetas/1994 Direct + indirect 648 (378–1,423) 37
Hospital Data driven Laboratory tests,
prophylaxis (including 7
d off work), medical
visits, lost productivity
(exposed HCP and
visiting staff)
Direct + indirect … Direct + indirect 325 (NC) US$/1998 Direct + indirect 317 The study includes
(separately) the costs of
measures taken to reduce
injury rates. The cost-
effectiveness is $4,000 per
injury prevented.
17
Hospital Data driven Laboratory tests,
prophylaxis, medical
visits, lost productivity
(exposed HCP)
Direct/
indirect
No Direct + indirect
Direct
Indirect
1,121
1,005 (NC)
116 (NC)
Euro/2000 Direct + indirect
Direct
Indirect
1,691
1,516
175
Total occupational exposures
cost in 1 year: €68,310; mean
= €281; median = €250;
36
Societal Data driven Laboratory tests, treatment,
medical visits,
medication, lost
productivity (exposed
HCP and visiting staff),
management of HIV PEP
side effects, emotional
distress and anxiety
Direct/indirect No Direct + indirect
Direct
Indirect
159 (145–201)
38 (37–39)
121 (107–163)
US$/2004 Direct + indirect
Direct
Indirect
199 (182–252)
48 (46–49)
152 (134–204)
NSI management annual cost:
range: $25,896–$36,066.
Direct + indirect costs per
injured nurse: mean = $259;
(range, $235–$328); direct
costs per injured nurse:
mean = $113 (range, $89.7–
$182.2); indirect costs: mean
= $146.
34
NHS Modeling Laboratory tests, treatment,
medical visits, medical
instruments; lost
productivity (exposed
HCP and visiting staff),
overhead
Direct + indirect NA Direct + indirect 388 (172–1,502) Euro/
2002
Direct + indirect 714 (317–2,765) 22
Hospital
and
NHS
Modeling Laboratory tests, treatment,
medical visits, lost
productivity (exposed
HCP and visiting staff)
Direct/
indirect
Yes Direct + indirect
Direct
Indirect
850 (750–1,320)
586 (516–910)
265 (233–411)
Euro/2005 Direct + indirect
Direct
Indirect
1,324 (1,168–2,056)
913 (804–1,417)
413 (363–640)
NSI management annual
cost: 36 million euros
30
Hospital Data driven Laboratory tests, treatment,
nurse and medical visits
Direct + indirect NA Direct + indirect 220 Euro/2003 Direct + indirect 418 Cost-effectiveness for avoided
injury adopting SEDs: IV
catheters: €2.65; hypodermic
syringes: €869.79; butterfly
needles €1,195.99; needleless
administration sets
€4,954.55; short IV catheters:
€31,563.91.
29
Table 2. Continued
Perspective Approach Determinants of Cost Type of Costa
Costs
According
to the CDC
Definitionb
Weighted Mean
Cost per Injury,
Int$ (Range) Currency/Year
Value per Injury,
Int$ (Range)c
Comments on
Economic Results
Study
(Reference)
Societal Modeling Laboratory tests, treatment,
medical visits, lost
productivity (exposed
HCP)
Direct/indirect Yes Direct + indirect
Direct
Indirect
596
339
257
US$/2004 Direct + indirect
Direct
Indirect
747
425
322
National annual costs: tests:
$103,125,746; lost
productivity: $81,187,457;
subsequent infections:
$4,186,548
Total cost for injuries:
$188,499,751
35
Hospital Data driven Laboratory tests, treatment,
lost productivity
(exposed HCP and
visiting staff), additional
wages for management
of HIV PEP side effects
Direct + indirect NA Direct + indirect 1,161 (71–4,838) US$/2003 Direct + indirect 1,470 (90–6,127) Mean cost related to the
infectious status of the
source:-$2,456 if positive for
HIV (HBV, HCV included);
$650 if positive for HCV;
$376 for not infected/
unknown source
24
NHS Modeling Laboratory tests, treatment,
medical visits
Direct Yes Direct 2,513 Swedish kronor
(SEK)/2007
Direct 294 Adopting safety devices reduces
annual cost by €843,426.
31
University
(training
school)
Data driven Laboratory tests; treatment;
medical visits
Direct Yes Direct 149 US$/2007 Direct 170 8
Hospital Modeling Laboratory tests, treatment,
medical visits, lost
productivity (exposed
HCP and visiting staff),
compensation and
litigation
Direct/indirect No Direct + indirect
Direct
Indirect
867 (273–2,060)
617 (250–1,189)
250 (23–606)
Euro/2012 Direct + indirect
Direct
Indirect
1,049 (331–2,493)
747 (303–1,439)
303 (28–734)
Direct costs: €210.01 (low-risk
injuries, 61% of exposures)
and €950.34 (high-risk
injuries, 39%)
Indirect costs: €63.22 (low
risk) and €844.22 (high risk)
32
Hospital Data driven Laboratory tests, treatment,
medical visits, surgical
treatment, lost
productivity (exposed
HCP)
Direct Yes Direct 119,673 Korean
won ($125)
Korean won
and US
dollar
(955:1)/2006
Direct 173 Laboratory tests account for
52.6% of the cost (45.9% for
the HCP). Mean NSI
management cost is higher in
Seoul ($139) vs the suburbs
($80). Regarding indirect
costs, there were no lost
working days among the
exposed HCP in the study.
25
NOTE. Int$, 2015 International US dollars; HBV, hepatitis B virus; HCP, healthcare personnel; HCV, hepatitis C virus; HIV, human immunodeficiency virus; i.v., intravenous; NA, not applicable; NC, not
computable; NHS, National Health System; NSI, needlestick and sharps injury; PEP: post-exposure prophylaxis; SEDs, safety-engineered devices.
aDirect + indirect: aggregated costs; direct/indirect: disaggregated costs.
bData on categorization of the costs adapted according to Centers for Disease Control (CDC): direct costs include laboratory tests, treatment, medical visits; indirect costs include lost productivity, time-off
productivity.
cInjury management costs were expressed in national currencies of 2015 using the national inflation rates provided by the World Bank (http://data.worldbank.org/indicator/fp.cpi.totl.zg), then these were
converted to 2015 International US$ (Int$) using purchasing power parity (ppp) exchange rates (http://data.worldbank.org/indicator/pa.nus.ppp).
Furthermore, in a single study, the source and HCP were
also screened for syphilis, and in some cases, the source was
screened for hepatitis A virus. These tests account respectively
for 13.4% and 1.7% of the total tests performed in the study
period.25
The antiretroviral HIV PEP regimen was specified in 8 of 13
studies. In 6 studies conducted between 1990 and 2003,
a zidovudine-based regimen was adopted alone (in 1 study)34
or in combination with lamivudine, including a protease
inhibitor according to risk (indinavir in 3 studies17,22,33;
nelfinavir in 2 studies29,36). In 2 more recent modeling studies
(2006 and 2013), a protease inhibitor-based regimen with
lopinavir/ritonavir was considered, adding zidovudine/lami-
vudine30 or tenofovir/emtricitabine32 (Table 5).
Finally, administration of hepatitis B immune globulin
(HBIG) and HBV vaccination were included in the direct costs
of an NSI in eight22,24,25,29,30,33,35,37 and seven24,25,30,33,35 stu-
dies, respectively (Table 5); in a single hospital study, HBV
vaccination was administered but not included in the direct
costs because the charges were borne by the NHS.29
Regarding indirect costs, 10 studies17,22,24,30,32-37 included
lost productivity of an exposed HCP (eg, for initial reporting
and treatment, follow-up appointments, and additional work
time missed due to PEP side effects); 1 study32 included also
compensation and litigation costs (Table 5).
Quality of the Studies
The quality of the studies is presented in Table 6. For all
investigations, the research question (item #1), economic
importance of the research question (#2), viewpoints of the
analysis (#3), primary outcome measures for the economic
evaluation (#11), time horizon of costs and benefits (#22), and
conclusions from the data reported (#34) were stated.
Three studies presented the incremental analysis (#31),
provided details of the design and results of effectiveness (#9),
and used a synthesis method or meta-analysis of estimates
(#10): the data-driven study by Armadans Gil, which had the
highest quality score (97%),29 and 2 modeling studies, Leigh
(96%)35 and Hanmore (94%).32 These 3 studies
reported very different values of aggregate direct + indirect
costs, with means of Int$418, Int$747, and Int$1,049,
respectively.
discussion
The overall aggregate direct + indirect costs for managing an
NSI ranged from Int$650 to Int$750, considering the median
and mean value of the mean costs borne by the hospital or
NHS to manage exposures with different scenarios. These
values were derived from both modeling and data-driven
studies conducted across different countries and continents
over a period of approximately 20 years.
Indirect costs are relatively consistent between studies; they
mostly refer to lost productivity, which is usually calculated in
minutes spent in baseline and follow-up visits by the exposed
HCP and more rarely on days of staff absence; the median and
mean values of the mean indirect costs ranged between Int
$175 and Int$350.
Direct costs vary. The wide range of possible scenarios
regarding the infectivity of the source, the susceptibility of the
table 3. Distribution of Studies of Economic Analysis on Occu-
pational Needlestick and Sharps Injuries Among Healthcare Person-
nel According to Type of Provided Costs and Study Approach
Type of Approach
No. of
studies Type of Cost
Data
Driven Modeling
3 Direct costs 2 1
6 Direct/indirect costs
(disaggregated)
3 3
5 Direct + indirect costs
(aggregated)
3 2
14 Total 8 6
table 4. Description of the Distribution of the Means of the Costs for Managing a Single Percutaneous Injury (2015 International US
Dollars)
Means of the Costs for Managing a Single NSI
Approach Type of Cost No. of Studies Median Mean SD Min Max
Data driven Direct 5 173 521 610 48 1,516
(N= 8) Indirect 3 175 232 119 152 369
Direct + indirect 6 656 831 630 199 1,691
Modeling Direct 4 586 595 285 294 913
(N= 6) Indirect 3 322 346 59 303 413
Direct + indirect 5 747 897 284 649 1,324
All (N= 14) Direct 9 425 554 467 48 1,516
Indirect 6 322 286 117 152 413
Direct + indirect 11 747 861 482 199 1,691
NOTE. NSI, needlestick and sharps injury.
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table 5. Description of Cost Items Included in 14 Studies of Economic Analysis on Occupational Needlestick and Sharps Injuries Among Healthcare Personnel, 1997–2013
Direct costs Indirect costs
Study
(Reference)
Laboratory Tests
Drugs
HIV-PEP HBV Vaccine HBIG
Subsequent
Occupational Infection
Post-Exposure
Counseling/visit Lost Productivity Others
Detailed costs; decision
algorithm not specified
AZT + 3TC + IDV (cost
for a 4-week treatment)
Cost for 3 doses and
booster dose; cost in
hospital A includes
blood test
Hospital A: cost per
dose; hospital B:
cost for 5 doses
Not included Cost depending on
simple, moderate,
and extensive risk
Hospital A: average;
hospital B: not
included
Not included 33
Detailed costs; baseline
screening for HBV of the
source always performed,
regardless of HCP vaccinal
status; baseline HCP
screening for HCV and HIV
depending on the serostatus
of the source
Not performed (no HIV
exposures)
Not included (charge
borne by NHS)
Cost/dose included in
the “post-
exposure
counselling/visit”
cost
Not included Cost/min for physician,
nurse and support
staff
Cost/min Overheads 37
Non-detailed costs; decision
algorithm not specified;
baseline screening of the
source and HCP for HBV,
HCV and HIV is always
performed.
AZT or ddI + PI;
costs include an average
of 14 days of PEP and
tests to detect drug
toxicity and a week off
work
Not included Not performed Not included Not included Only for those who
took HIV-PEP,
evaluated using
the average gross
salary for nurses
and included in
PEP cost
Not included 17
Detailed costs; source screening
for HBV depending on the
HBV serostatus of the HCP;
baseline HCP screening for
HCV and HIV depending on
the serostatus of the source
Average cost.
AZT/3TC + NFV
(1 case switched to
d4T + ddI + IDV)
Not performed (no HBV exposure) No subsequent
occupational
infection
Cost/injury for
physician, nurse,
consultant, and
support staff
Cost/injury Not included 36
Detailed costs; decision
algorithm not specified
AZT alone regimen
+ 1 multidrug regimen
Not included Not included Not included Cost/injury for
employee health
department, primary
care physician, and
consultant visit
Average Not included 34
Detailed costs; baseline
screening for HBV of the
source is always performed,
regardless of HCP vaccinal
status. Baseline HCP
screening for HCV and HIV
depending on the serostatus
of the source
AZT + 3TC + IDV (cost
includes tests to detect
drug toxicity)
Not included (charge
borne by NHS)
Cost/dose included in
the “post-
exposure
counselling/visit”
cost
Not included Cost/min for physician,
nurse, and support
staff
Cost/min for
physician, nurse
and support staff
Overheads 22
Detailed costs; baseline
screening of source and HCP
and FU not explicitly
reported, but deriving from
available national guidelines
AZT/3TC+ LPV/r (cost for
a 4-wk treatment)
Cost/dose Cost/2 doses Only 24-wk treatment
for HCV infection
Cost/min for employee
health department
and physician visit
Cost/visit for
exposed doctor
and nurse
Not included 30
Detailed costs; baseline
screening of the HCP for
HCV and HIV is always
performed regardless of the
serostatus of the source;
baseline screening for HBV,
HCV and HIV of the source
is performed if unknown
AZT + 3TC + NFV (cost
includes tests to detect
drug toxicity)
Not included (charge
borne by NHS)
Cost/dose Not included Cost/injury for
physician and nurse
Not included Not included 29
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Non-detailed costs; decision
algorithm not specified
Regimen not specified. Cost
included test and HIV-
PEP
Not specified; cost included test and HBV-PEP HBV/HCV/HIV
lifetime medical cost
Not included Cost depending on
intensity of
follow-up, and
subsequent
chronic HBV,
chronic or acute
HCV, or HIV
infection
Not included 35
Average cost; decision algorithm
not specified
Regimen not specified;
average cost
Cost included both HBV and HIV-PEP (no
source patients mono-infected with HBV)
Not included Mean cost and range for
initial evaluation,
exposure
management, and
follow-up visits
Mean cost and
range for initial
evaluation,
exposure
management,
and follow-up
Not included 24
Detailed costs; baseline HCP
screening for HBV, HCV,
and HIV, depending on the
serostatus of the source
Regimen not specified; cost
for a 4-wk treatment
Cost/dose Not included Not included Cost/visit for nurse,
infectious disease
specialist, and
psychiatric
consultant
Not included Not included 31
Detailed costs; baseline HCP
screening for HBV, HCV,
and HIV, depending on the
serostatus of the source
Regimen not explicitly
reported, but deriving
from available national
guidelines;
total cost for all
exposures
Not performed (no HBV exposure in
unvaccinated HCP)
Not included Total cost for initial
evaluation, exposure
management,
follow-up, and
emergency
department visits
Not included Not included 8
Non-detailed costs; decision
algorithm not specified
TDF/FTC + LPV/r for
4 weeks; average cost for
low- and
high-risk NSIs, including
both HBV- and
HIV-PEP
4 doses for
unvaccinated and 1
booster dose for
vaccinated HCP;
average cost for low-
and
high-risk NSIs,
including both HBV-
and HIV-PEP
Not included HBV/HCV/HIV
subsequent infection
Average cost for low-
and
high-risk NSIs
Average cost for
low- and
high-risk NSIs
Compensation and
litigation
32
Average costs; no decision
algorithm
Regimen not specified;
average cost/injury
Average cost/injury (cost included both HBV
vaccine and HBIG)
Not included Average cost/injury for
medical
consultations and
surgical treatment
No lost productivity
among the
exposed HCP
Not included 25
NOTE. 3TC, lamivudine; AZT, zidovudine; d4T, stavudine; ddI, didanosine; FU, follow-up; HBIG, hepatitis B immune globulin; HBV, hepatitis B virus; HCV, hepatitis C virus; HCP,
healthcare personnel; HIV, human immunodeficiency virus; IDV, indinavir; LPV/r, lopinavir/ritonavir; NFV, nelfinavir; NHS, National Health Service; NSI, needlestick and sharps injury;
PEP, post-exposure prophylaxis; PI: protease inhibitor; TDF/FTC: tenofovir/emtricitabine.
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exposed HCP, and the post-exposure diagnostic and prophy-
lactic protocol account for the differences in the average direct
costs within and between considered studies, particularly when
analyzing studies using a different approach. In modeling
studies, the source and exposed HCP are tested according to an
optimized protocol. Prophylaxes are provided to all susceptible
HCP, and those protocols are always considered to have been
completed. All exposed HCP attend follow-up visits and test-
ing. In real life, HCP anxiety can influence the choice of
baseline and follow-up testing, or the source situation may be
more complicated (eg, multiple possible sources, need for
supplemental, confirmatory testing, etc.). Acceptance, adher-
ence, and completion rate of prophylactic treatments may be
suboptimal; regimens may vary and cause adverse reactions
requiring additional interventions; and compliance with
follow-up protocols may differ.
Moreover, regardless of the approach, treatment costs vary
between studies: the standard antiretroviral PEP regimen chan-
ged significantly over time, including different combinations
and newer, more tolerable and expensive drugs in recent studies.
Variations in HBIG dosage among protocols increased costs up
to 4-fold, and diagnostic tests evolved over time. Two recent
modeling studies considering direct and indirect costs and using
newer antiretrovirals had a median cost of Int$1,187 (range, Int
$1,049–Int$1,324)30,32; however, too few recent studies are
available to define a real and current overall cost.
Notwithstanding all the observed differences, comparisons
between studies also identified significant similarities. There-
fore, considering the wide range of possible situations, settings,
and behaviors covered in selected studies, this overall amount
(including direct and indirect costs) should represent a reliable
estimate of the actual average cost for managing an NSI.
However, the wide range of observed values should be taken
into due account to avoid under- or overestimating the
economic costs of managing these incidents or the potential
savings resulting from their prevention.
A cautious interpretation of these findings is warranted. The
literature search may be incomplete; moreover, different
periods, countries, and study designs were compared. Part of
the heterogeneity due to the approach and type of estimated
costs was controlled by stratifying the studies. Furthermore,
weighted means were calculated where disaggregated costs
were available. However, this was not possible for all the
studies considered. The effect of this heterogeneity is evident in
the high variability (SD of the mean and width of the range) of
the estimates. In addition, Drummond’s checklist was
designed to include all possible aspects concerning economic
evaluations, but in this review, different study designs were
compared, and it was not possible to apply all items to all
articles. To eliminate disparities between the studies, a quality
score was calculated based on the items considered appropriate
for each study.
Despite these issues, this review confirms that the economic
impact of managing NSIs is not negligible, and our analysis
provides clues about where to reduce costs.
Protocols should be optimized based on the source; HCP
vaccination should increase, and the response should be
appropriately evaluated post-vaccination and readily available
in case of injury. This recommendation is clearly demon-
strated in the high-quality study by Armadans Gil et al,29 where
most exposures involved vaccinated HCP exposed to known
sources who tested negative for HCV and HIV; the mean NSI
management cost (direct + indirect) was Int$418.
Additional strategies to reduce costs could include the fol-
lowing: using rapid HIV tests to assess the source serostatus,
thus avoiding unnecessary PEP, tests, and anxiety for the
table 6. Quality Results of the Selected Studies of Economic Analysis on Occupa-
tional Needlestick and Sharps Injuries Among Healthcare Personnel, 1997–2013
Author Year Total Score Maximum Scorea Quality %
Jagger J33 1998 74 107 69
Solano Bernad VM37 1998 96 113 85
Roudot-Thoraval F17 1999 62 107 58
Nidegger D36 2003 63 79 80
Lee WC34 2005 72 85 85
Solano VM22 2005 72 89 81
Cazzaniga S30 2006 93 116 80
Armadans Gil L29 2006 107 110 97
Leigh JP35 2007 82 85 96
O’Malley EM24 2007 80 107 75
Glenngård AH31 2009 66 107 62
Fica CA8 2010 71 91 78
Hanmore E32 2013 106 113 94
Oh HS25 2013 65 79 82
aMaximum score represents the expected score if the study was conducted with optimal
practices. Different Maximum scores were shown because different study designs were
reviewed according to Drummond’s scale.28
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exposed HCP,38 and implementing tests for the early detection
of bloodborne infections, which can shorten follow-up
periods (eg, HIV-Ab/Ag test) and allow for early diagnosis
at a lower cost (eg, HCV core-antigen testing replacing
HCV-RNA).
Even if none of the retrieved studies included HCV-RNA
testing in post-exposure protocols, it is recommended as
alternative strategy in the United States and is strongly
supported in a cost-effectiveness analysis. HCV-RNA testing at
1 month, at an average cost of Int$242 per exposure, leads to
earlier detection of HCV transmission and lowers the risk of
progression to chronic hepatitis.39 Consequently, NSI man-
agement costs could also increase, and even more in the future,
if direct-acting antivirals for hepatitis C are used in PEP, which
would add a significant cost to treating these frequent events.
Are these costs truly representative of this issue? The costs of
treating an occupational infection were not included in the
calculation of average NSI costs, nor were those of litigation
and compensation. Bloodborne infections other than HBV,
HCV, or HIV were not considered, though many different
pathogens can be, and have been, occasionally transmitted
through an NSI. Most importantly, intangible costs arising
from an NSI were not evaluated. The single willingness-to-pay
analysis identified in the literature reported that the high
median amount HCP were willing to pay to avoid a sharps-
related injury were Int$828 in the base case and Int$1,237
when exposed to HIV or HCV. This finding suggests that the
costs of intangible aspects of HCP injuries, such as anxiety and
distress, could equal costs associated with the medical evalua-
tion of these injuries.40 However, in this study, the median
time from injury to interview was 3 days. Thus, the interviewed
subjects had not yet experienced the impact of being at risk of
developing a bloodborne infection or the effects on personal
and family life, sexual relationships, reproductive plans,
breastfeeding, or professional expectations, which would
increase the amounts reported above.
In conclusion, NSIs generate significant direct, indirect,
potential, and intangible costs. While the costs for their pre-
vention may seem high in the beginning, ultimately they prove
to be the opposite. The economic expenditures directed
toward enhancing interventions to prevent occupational
exposures and infections, including provision of SEDs, will
likely decrease over time, while enhancing HCP perception of
their own value and affecting the quality of the care they pro-
vide. As highlighted in the preamble of the EU Directive,
“Health and safety of workers is paramount and is closely
linked to the health of patients.”
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